Evidence map›Paper›PMID 32070047›Full record

ArticleNanomaterials (Basel, Switzerland)2020

Fabrication of Supercritical Antisolvent (SAS) Process-Assisted Fisetin-Encapsulated Poly (Vinyl Pyrrolidone) (PVP) Nanocomposites for Improved Anticancer Therapy.

Lin-Fei Chen, Pei-Yao Xu, Chao-Ping Fu, Ranjith Kumar Kankala, Ai-Zheng Chen, Shi-Bin Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lin-Fei ChenDepartment of Chemical Engineering and Pharmaceutical Engineering, College of Chemical Engineering, Huaqiao University, Xiamen 361021, China.
Pei-Yao XuDepartment of Chemical Engineering and Pharmaceutical Engineering, College of Chemical Engineering, Huaqiao University, Xiamen 361021, China.
Chao-Ping FuInstitute of Biomaterials and Tissue Engineering, Huaqiao University, Xiamen 361021, China.
Ranjith Kumar KankalaDepartment of Chemical Engineering and Pharmaceutical Engineering, College of Chemical Engineering, Huaqiao University, Xiamen 361021, China.
Ai-Zheng ChenDepartment of Chemical Engineering and Pharmaceutical Engineering, College of Chemical Engineering, Huaqiao University, Xiamen 361021, China.
Shi-Bin WangInstitute of Biomaterials and Tissue Engineering, Huaqiao University, Xiamen 361021, China.

Funding

National Natural Science Foundation of China U1605225, 81971734, and 31800794
6 · The paper itself

Abstract

Due to its hydrophobicity, fisetin (FIS) often suffers from several limitations in terms of its applicability during the fabrication of pharmaceutical formulations. To overcome this intrinsic limitation of hydrophobicity, we demonstrate here the generation of poly (vinyl pyrrolidone) (PVP)-encapsulated FIS nanoparticles (FIS-PVP NPs) utilizing a supercritical antisolvent (SAS) method to enhance its aqueous solubility and substantial therapeutic effects. In this context, the effects of various processing and formulation parameters, including the solvent/antisolvent ratio, drug/polymer (FIS/PVP) mass ratio, and solution flow rate, on the eventual particle size as well as on distribution were investigated using a 2

Indexed as

antitumorfisetinnanofabricationsupercritical fluid technology

Identifiers

PMID32070047
PMCPMC7075186

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.